Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBelluscura Regulatory News (BELL)

Share Price Information for Belluscura (BELL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 8.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (13.333%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 8.00
BELL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) TMT Acquisition plc - Amended

1 Feb 2024 18:16

RNS Number : 7795B
Belluscura PLC
01 February 2024

AMENDMENT TO THE OPENING POISTION DISCLOURE WITH RNS NUMBER 0330R, PUBLISHED AT 07.00 ON THE 24 OCTOBER 2023.

Changes made to box 3(b) following agreement with the Takeover Panel regarding the Constitution of the Belluscura Concert Party

FORM 8 (OPD)

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

1. KEY INFORMATION

(a) Full name of discloser:

BELLUSCURA PLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

TMT ACQISITION PLC

(d) Is the discloser the offeror or the offeree?

OFFEROR

(e) Date position held:

The latest practicable date prior to the disclosure

23 OCTOBER 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES

BELLUSCURA PLC

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Class of relevant security:

Ordinary 4p shares

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

(2) Cash-settled derivatives:

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

TOTAL:

Nil

Nil

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

(a) Beneficial holdings of the Directors of Belluscura plc, together with the interests of persons acting in concert with Belluscura plc, (including their close relatives and the related trusts of either of them) in TMT Acquisition plc ordinary shares of 4p each

Name

Number of ordinary shares held

% of voting share capital

Nigel Wray & Family Trusts

2,700,000

9.81%

James Serjeant (1)

835,000

3.03%

Dowgate Group Limited (2)

625,000

2.27%

Stephen Hemsley

585,005

2.12%

Adam Reynolds

225,000

0.81%

Jonathan Serjeant

32,760

0.11%

Madeline Poutney

22,230

0.08%

Dowgate Capital - Discretionary Funds

234,002

0.85%

Dowgate Wealth - Discretionary Funds

3,077,622

11.19%

8,336,619

30.31%

(1) Total holdings of James Serjeant and close family members (of which 45,000 TMT Acquisition shares are non-beneficial interests held by close relatives). This excludes those TMT Acquisition shares held by Jonathan Serjeant who is also a member of the Belluscura Concert Party. James Serjeant is a director of TMT Acquisition plc and also, a director and shareholder of Dowgate Group Limited resulting in his interests in relevant securities also being disclosed in the offeree's Opening Position Disclosure.

(2) Dowgate Capital Limited, a wholly owned subsidiary of Dowgate Group Limited, is broker to both TMT Acquisition plc and to Belluscura plc, resulting in its interests in relevant securities also being disclosed in the offeree's Opening Position Disclosure. Dowgate Capital Limited is acting as financial adviser to Belluscura plc in relation to the offer. Dowgate Group Limited is deemed to be acting in concert with both Belluscura plc and TMT Acquisition plc. James Serjeant is a director and shareholder of Dowgate Group Limited.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Date of disclosure:

24 October 2023

Contact name:

Simon Carter

Telephone number:

020 3903 7723

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FEEBIGDDXBGDGSB
Date   Source Headline
13th Dec 20227:00 amRNSFirst international distribution agreement
14th Nov 20224:40 pmRNSSecond Price Monitoring Extn
14th Nov 20224:35 pmRNSPrice Monitoring Extension
14th Nov 20222:06 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
14th Nov 202211:05 amRNSSecond Price Monitoring Extn
14th Nov 202211:00 amRNSPrice Monitoring Extension
10th Nov 20227:00 amRNSBelluscura receives certification to ISO standard
31st Oct 20225:46 pmRNSHolding(s) in Company
31st Oct 20225:41 pmRNSDirector/PDMR Shareholding
31st Oct 20225:38 pmRNSDirector/PDMR Shareholding
24th Oct 20227:00 amRNSBelluscura wins two HME Business Awards
23rd Sep 202211:45 amRNSHolding(s) in Company
20th Sep 20227:01 amRNSHalf-year Report
20th Sep 20227:00 amRNSBelluscura signs agreement with US distributor
6th Sep 20227:00 amRNSNotice of Results
18th Aug 20221:25 pmRNSDirector/PDMR Shareholding
10th Aug 20227:00 amRNSDirector/PDMR Shareholding
2nd Aug 20222:26 pmRNSAgreement with VGM, largest MSO in US-replacement
2nd Aug 202212:53 pmRNSAgreement with VGM, largest DSO in US-replacement
2nd Aug 20227:00 amRNSSupply Agreement with VGA, largest MSO in the US
15th Jul 20227:00 amRNSWarrant Exercise
14th Jul 20227:00 amRNSExercise of Warrants
30th Jun 20227:00 amRNSDirect to Consumer Sales and Distribution Plan
27th Jun 20227:00 amRNSLaunch of Next Gen X-PLOR Oxygen Concentrator
25th May 20221:19 pmRNSTR-1: Notification of major holdings
24th May 20225:27 pmRNSTR-1: Notification of major holdings
19th May 20227:00 amRNSBelluscura Expands its Patent Portfolio
17th May 202212:00 pmRNSApplications Announcement
13th May 202211:00 amRNSResult of Placing
12th May 20225:01 pmRNSProposed placing to raise £5.0m
25th Apr 20221:00 pmRNSResult of AGM
21st Apr 20227:00 amRNSSenior Management Appointment
7th Apr 20227:00 amRNSDAPA Contract
5th Apr 20226:31 pmRNSHolding(s) in Company
5th Apr 20227:00 amRNSSenior Management Appointment
1st Apr 20227:00 amRNSNotice of AGM and Annual Report 2021
30th Mar 20227:00 amRNSManufacturing Agreement
22nd Feb 20227:00 amRNSFinal Results
27th Jan 202211:06 amRNSSecond Price Monitoring Extn
27th Jan 202211:00 amRNSPrice Monitoring Extension
24th Jan 20227:00 amRNSTrading Update and Notice of Preliminary Results
20th Jan 20222:32 pmRNSExercise of Warrants and Total Voting Rights
13th Jan 202211:05 amRNSSecond Price Monitoring Extn
13th Jan 202211:00 amRNSPrice Monitoring Extension
7th Dec 20217:00 amRNSExercise of Warrants and Total Voting Rights
29th Nov 20217:01 amRNSReimbursement approvals
29th Nov 20217:00 amRNSExercise of Warrants and Total Voting Rights
4th Nov 20217:00 amRNSTrading update
1st Nov 20217:00 amRNSThe Pulse: Healthcare Innovation Breakfast

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.